Novonesis A/S (NVZMY)
| Market Cap | 26.79B |
| Revenue (ttm) | 3.26B |
| Net Income (ttm) | 303.00M |
| Shares Out | n/a |
| EPS (ttm) | 1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.35 (0.63%) |
| Ex-Dividend Date | Sep 9, 2024 |
| Volume | 646 |
| Open | 57.55 |
| Previous Close | 57.26 |
| Day's Range | 57.47 - 57.55 |
| 52-Week Range | 49.99 - 72.50 |
| Beta | 0.52 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 7, 2024 |
About Novonesis
Novonesis A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotto... [Read more]
Financial Performance
In 2023, Novonesis's revenue was 17.90 billion, an increase of 1.97% compared to the previous year's 17.55 billion. Earnings were 3.02 billion, a decrease of -17.74%.
Financial numbers in EUR Financial StatementsNews
Novonesis A/S (NVZMF) Q3 2024 Earnings Call Transcript
Novonesis A/S (OTCPK:NVZMF) Q3 2024 Earnings Conference Call November 7, 2024 3:00 AM ET Company Participants Tobias Cornelius Björklund - Head, Investor Relations Ester Baiget - Chief Executive Offic...
Novonesis: Underperformance In Price, But Now I'm Buying (Rating Upgrade)
Novonesis, formed from Chr. Hansen and Novozymes, shows promising growth but remains overvalued with a current P/E of 33x. Find out why I rate NVZMF stock a buy.
Novozymes A/S (NVZMF) Q2 2024 Earnings Call Transcript
Novozymes A/S (OTCPK:NVZMF) Q2 2024 Results Conference Call August 28, 2024 3:00 AM ETCompany ParticipantsTobias Björklund - Head of Investor RelationsEster...
Novozymes A/S reports 1H results
Invitation to an extraordinary shareholders' meeting of Novozymes A/S
An extraordinary shareholders' meeting of Novozymes A/S will be held on Monday March 4, 2024 at 4:00 pm CET at Boege Alle 10-12, 2970 Hoersholm, Denmark.
The Novozymes Report 2023
This annual report has been released subsequent to the approval of the combination of Novozymes and Chr. Hansen on January 29, 2024.
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed February 2, 2024 Company announcement No.
Novozymes A/S (NVZMF) Q4 2023 Earnings Call Transcript
Novozymes A/S (NVZMF) Q4 2023 Earnings Call Transcript
Legacy Novozymes delivers solid last full-year results
Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last...
Completion of the combination between Novozymes and Chr. Hansen
January 29, 2024 – Company announcement no. 2 Please see attachment.
The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner
Today, the proposed combination of the legacy companies Novozymes and Chr. Hansen is successfully completed, establishing the company Novonesis. Novonesis is a world-leading biosolutions partner for b...
All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen
January 26, 2024 – Company announcement no. 1 Please see attachment.
Novozymes CEO is confident its merger with Chr. Hansen will close in Q1
Novozymes CEO Ester Baiget discusses the Danish biotechnology company's planned combination with with fellow biotech firm Chr. Hansen.
Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted
December 20, 2023 Please see attachment. Contact information Investor Relations Disa Tuominen+45 6038 5826 dkditu@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-hansen.com A...
Novozymes' updated financial calendar
Please read the full announcement in PDF Attachment 2023_61_Updated_financial_calendar
Novozymes and Chr. Hansen announce name of future combined company; Novonesis
Novozymes and Chr. Hansen have announced that the name of the future combined company will be ‘Novonesis'. Novonesis means ‘A new beginning' and derives from the Greek word ‘genesis'. The name reflect...
Update on the merger approval process for the combination of Novozymes and Chr. Hansen: Conditional competition clearance from the European Commission obtained
December 12, 2023 Please see attachment. Contact information Investor Relations Disa Tuominen+45 6038 5826 dkditu@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-hansen.com A...
Exclusive: Novozymes, Chr. Hansen tie-up likely to win EU nod, sources say
Danish food ingredients and enzymes makers Novozymes and Chr. Hansen are expected to secure EU antitrust approval for their all-share $22 billion tie-up based on remedies offered to address competitio...
Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.
November 20, 2023 Please see attachment. Contact information Investor Relations Anders Mohr Christensen+45 2515 2364 dkamc@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-han...
Novozymes launches Quara® LowP for renewable diesel feedstock pre-treatment
Novozymes, a global leader in biosolutions, marks a significant milestone in the renewable diesel and SAF (Sustainable Aviation Fuel) industry with the launch of Quara® LowP, an enzymatic solution des...
Novozymes A/S (NVZMF) Q3 2023 Earnings Call Transcript
Novozymes A/S (OTCPK:NVZMF) Q3 2023 Results Conference Call October 26, 2023 3:00 AM ET Company Participants Tobias Cornelius Björklund - Head, Investor Relations Ester Baiget - Chief Executive Office...
We're 'very pleased' with our results, says Novozymes CEO
Ester Baiget, CEO of Novozymes, discusses the company's third-quarter earnings.
Novozymes accelerates growth in Q3 and is on track to deliver on full-year expectations
After the first nine months of the 2023 financial year, Novozymes sees increasing demand for sustainable biosolutions and delivers 5 % organic sales growth. The full-year organic sales growth outlook ...
Novozymes: Close To Being A Buy Again
Novozymes' stock is declining for almost two years and has lost almost 50% of its previous value. The company reported mediocre half-year results for fiscal 2023. But Novozymes has a wide economic moa...
Novozymes announce the Executive Leadership Team and organizational structure for the future combined company of Novozymes and Chr. Hansen
October 10, 2023 Please see attachment. Contact information Investor Relations Anders Mohr Christensen+45 2515 2364 dkamc@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-hans...